**Postmenopausal Osteoporosis**

**Lauren Goeser, PharmD,** [**lgoeser@iuhealth.org**](mailto:lgoeser@iuhealth.org)

**January 19, 2022**

**References**

1. Black DM, Schwartz AV, Ensrud KE, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-2938.
2. Calcitonin. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: [http://online.lexi.com](http://online.lexi.com/). Accessed November 11, 2021.
3. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. *Endocr Pract* 2020;26:564-570.
4. Cauley JA, Robbins J, Chen Z, et al; Women’s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003;290:1729-1738.
5. Chlebowski RT, Hendrix SL, Langer RD, et al; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003;289:3243-3253.
6. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016; 375:1532-1543.
7. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.
8. Cummings SR, San Martin J, McClung MR, et al; for the FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765.
9. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641- 1647.
10. Denosumab. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: [http://online.lexi.com](http://online.lexi.com/). Accessed November 13, 2021.
11. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996;276:1389-1396.
12. Estrogens (Conjugated/Equine) and Bazedoxifene. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: [http://online.lexi.com](http://online.lexi.com/). Accessed November 13, 2021.
13. Ettinger B, Black DM, Mitlack BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645.
14. Fig. 1. Osteoclast and osteoblast from “Medizzy,” medizzy.com/feed/756698. Accessed 14 December. 2021Kanis JA, Melton LF 3rd, Christiansen C, Johnston CC, Khaltaev N. The Diagnosis of osteoporosis. *J Bone Miner Res* 1994;9:1137-1141.
15. Fig. 2. DEXA Body Scan from “Crossfit Invictus,” crossfitinvictus.com/fitness/sp/Invictus-nutrition. Accessed 14 December 2021.
16. Fig. 3. The role of RANK/RANKL/OPG pathway in bone loss from: Healthplexus. Accessed 14 December 2021. Amgen Canada Inc. CC.
17. Manson JE, Hsia J, Johnson KC, et al; Women’s Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
18. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A doubleblind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998;128:253-261.
19. NAMS Position Statement. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause: *The Journal of The North American Menopause Society*. Vol. 28, No. 9, pp. 973-997. DOI: 10.1097/GME.00000000001831.
20. Raloxifene. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: [http://online.lexi.com](http://online.lexi.com/). Accessed November 13, 2021.
21. Romosozumab. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: [http://online.lexi.com](http://online.lexi.com/). Accessed November 13, 2021.
22. Saag KG, Petersen J, Brandi ML et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017; 377:1417-1427.
23. Teriparatide. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: [http://online.lexi.com](http://online.lexi.com/). Accessed November 13, 2021.
24. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 2003;289:2673-2684.
25. Watts, N. “Figure 1”. The Fracture Risk Assessment Tool (FRAX): applications in clinical practice. *Journal of women’s health*. 2011. DOI: 10.1089/jwh.2010.2294.